Envveno Medical Corp (NVNO)

$0.35 +0.01 (3.74%)
Market Cap 6.91M
Revenue (ttm) 0.00
Net Income (ttm) -21.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 273,100
Avg Vol 582,680
Day's Range N/A - N/A
Shares Out 20.22M
Stochastic %K 69%
Beta 1.06
Analysts Hold
Price Target $12.50

Company Profile

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops e...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 261 2900
Address:
70 Doppler, Irvine, United States
Bangerplays
Bangerplays Dec. 24 at 5:02 PM
$NVNO added starter here
0 · Reply
Ripper98
Ripper98 Dec. 19 at 5:40 AM
$PFSA $INTS $NVNO FAVORITES
0 · Reply
NovaX234
NovaX234 Dec. 17 at 4:17 PM
$NVNO taking some here looks prime and tha gap fill is beautiful
0 · Reply
Ripper98
Ripper98 Dec. 17 at 3:29 PM
$PFSA $PCSA $NVNO $INTS
1 · Reply
tuckerabbott
tuckerabbott Dec. 15 at 5:39 PM
$NVNO i wonder what Robert Berman thinks when he sees what he has done. What a disgrace.
3 · Reply
JohnTrack
JohnTrack Dec. 12 at 9:18 PM
$NVNO Reverse split? total garbage! https://www.rapidticker.com/news/nvno-sec-filing-62ed51
1 · Reply
SPYmyQQQ
SPYmyQQQ Dec. 10 at 3:33 PM
🚀 New Signal ✅ 💊 $NVNO 🗓️ Dec 10, 2025 💵 Entry: $0.3418 🎯 Target (Opt.): $0.3934 (+15.10%) 👉 FREE TRIAL! spymyqqq/join/
1 · Reply
Ripper98
Ripper98 Dec. 9 at 1:51 AM
$PFSA $INTS $NVNO
0 · Reply
Ripper98
Ripper98 Dec. 8 at 6:32 PM
$PFSA $NVNO $INTS
0 · Reply
Icemanja
Icemanja Dec. 8 at 3:53 PM
$NVNO Someone please correct me if i'm wrong on these two points. Did they not say hemodynamic measurements were included in the original application? Now they say the valve Stainless Steel shell was too thick to accurately scan for hemodynamic measurements. Also before the FDA failure, myself and a few others asked how much it would cost to commercialize VenoValve at that time they said the cost would be low due to the multicenter trial and using the same pretrained doctors to roll it out. But now they state it would have cost 150 million. Since when did 150 million commercialize become low cost.
1 · Reply
Latest News on NVNO
enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment

Nov 26, 2025, 8:48 AM EST - 4 weeks ago

enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment

enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve

Nov 13, 2025, 5:00 PM EST - 5 weeks ago

enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve

enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 31, 2025, 8:05 AM EDT - 7 weeks ago

enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update

enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

Sep 26, 2025, 8:45 AM EDT - 3 months ago

enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

enVVeno Medical Updates Regulatory Status of VenoValve(R)

Sep 15, 2025, 8:45 AM EDT - 3 months ago

enVVeno Medical Updates Regulatory Status of VenoValve(R)

enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)

Aug 20, 2025, 7:00 AM EDT - 4 months ago

enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)

enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 15, 2025, 9:21 AM EDT - 4 months ago

enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

Aug 6, 2025, 8:30 AM EDT - 5 months ago

Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company

Aug 4, 2025, 9:05 AM EDT - 5 months ago

enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 1, 2025, 8:00 AM EDT - 5 months ago

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update

enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 5 months ago

enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

Jun 6, 2025, 8:05 AM EDT - 7 months ago

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

May 19, 2025, 8:05 AM EDT - 7 months ago

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

May 13, 2025, 8:45 AM EDT - 8 months ago

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

May 1, 2025, 8:05 AM EDT - 8 months ago

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

Apr 23, 2025, 8:00 AM EDT - 8 months ago

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

Apr 16, 2025, 8:30 AM EDT - 9 months ago

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

Mar 31, 2025, 9:00 AM EDT - 9 months ago

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

Feb 28, 2025, 8:00 AM EST - 10 months ago

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 11 months ago

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Feb 19, 2025, 8:45 AM EST - 11 months ago

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Feb 7, 2025, 9:00 AM EST - 11 months ago

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

Dec 16, 2024, 8:50 AM EST - 1 year ago

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

Nov 27, 2024, 8:30 AM EST - 1 year ago

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

Nov 20, 2024, 8:30 AM EST - 1 year ago

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Nov 19, 2024, 8:15 AM EST - 1 year ago

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Sep 24, 2021, 9:00 AM EDT - 4 years ago

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Hancock Jaffe To Rebrand As enVVeno Medical

Sep 22, 2021, 7:09 AM EDT - 4 years ago

Hancock Jaffe To Rebrand As enVVeno Medical

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

Sep 21, 2021, 4:00 PM EDT - 4 years ago

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Sep 15, 2021, 8:05 AM EDT - 4 years ago

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Sep 8, 2021, 7:43 PM EDT - 4 years ago

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

Sep 7, 2021, 8:05 AM EDT - 4 years ago

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Aug 19, 2021, 11:49 AM EDT - 4 years ago

Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Aug 19, 2021, 8:00 AM EDT - 4 years ago

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Hancock Jaffe Stock Surges On FDA Breakthrough Designation For Its Venous Insufficiency Device

Aug 3, 2021, 8:58 AM EDT - 4 years ago

Hancock Jaffe Stock Surges On FDA Breakthrough Designation For Its Venous Insufficiency Device

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

Aug 3, 2021, 8:05 AM EDT - 4 years ago

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Jul 8, 2021, 9:05 AM EDT - 4 years ago

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

Apr 23, 2021, 12:40 PM EDT - 5 years ago

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

First U.S. Patent Issues on Hancock Jaffe VenoValve

Apr 7, 2021, 1:40 PM EDT - 5 years ago

First U.S. Patent Issues on Hancock Jaffe VenoValve

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

Apr 5, 2021, 7:30 AM EDT - 5 years ago

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

Mar 8, 2021, 8:30 AM EST - 5 years ago

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

Jan 12, 2021, 8:30 AM EST - 5 years ago

Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

Hancock Jaffe Announces Executive Promotions

Dec 30, 2020, 4:15 PM EST - 5 years ago

Hancock Jaffe Announces Executive Promotions

Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements

Dec 21, 2020, 8:30 AM EST - 5 years ago

Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements

Bangerplays
Bangerplays Dec. 24 at 5:02 PM
$NVNO added starter here
0 · Reply
Ripper98
Ripper98 Dec. 19 at 5:40 AM
$PFSA $INTS $NVNO FAVORITES
0 · Reply
NovaX234
NovaX234 Dec. 17 at 4:17 PM
$NVNO taking some here looks prime and tha gap fill is beautiful
0 · Reply
Ripper98
Ripper98 Dec. 17 at 3:29 PM
$PFSA $PCSA $NVNO $INTS
1 · Reply
tuckerabbott
tuckerabbott Dec. 15 at 5:39 PM
$NVNO i wonder what Robert Berman thinks when he sees what he has done. What a disgrace.
3 · Reply
JohnTrack
JohnTrack Dec. 12 at 9:18 PM
$NVNO Reverse split? total garbage! https://www.rapidticker.com/news/nvno-sec-filing-62ed51
1 · Reply
SPYmyQQQ
SPYmyQQQ Dec. 10 at 3:33 PM
🚀 New Signal ✅ 💊 $NVNO 🗓️ Dec 10, 2025 💵 Entry: $0.3418 🎯 Target (Opt.): $0.3934 (+15.10%) 👉 FREE TRIAL! spymyqqq/join/
1 · Reply
Ripper98
Ripper98 Dec. 9 at 1:51 AM
$PFSA $INTS $NVNO
0 · Reply
Ripper98
Ripper98 Dec. 8 at 6:32 PM
$PFSA $NVNO $INTS
0 · Reply
Icemanja
Icemanja Dec. 8 at 3:53 PM
$NVNO Someone please correct me if i'm wrong on these two points. Did they not say hemodynamic measurements were included in the original application? Now they say the valve Stainless Steel shell was too thick to accurately scan for hemodynamic measurements. Also before the FDA failure, myself and a few others asked how much it would cost to commercialize VenoValve at that time they said the cost would be low due to the multicenter trial and using the same pretrained doctors to roll it out. But now they state it would have cost 150 million. Since when did 150 million commercialize become low cost.
1 · Reply
Icemanja
Icemanja Dec. 4 at 4:02 PM
$NVNO See what the real experts with 20 years of CVI testing data and FDA approved CVI supporting products have to say about using a stand alone valve as a solution. https://www.cookmedical.com/newsroom/what-a-medical-device-company-learned-from-discontinuing-a-clinical-trial/
5 · Reply
Ripper98
Ripper98 Dec. 4 at 6:13 AM
$PFSA Paris conference catalyst next week $INTS $NVNO
1 · Reply
haupman
haupman Dec. 3 at 10:20 PM
$NVNO this was always the case. The good news for bagholders is there is a long term path to $5 even after they dilute. (pre R/S).
2 · Reply
haupman
haupman Dec. 3 at 9:44 PM
$NVNO good news is that they can get the hemodynamic measurements from the enVVe due to a different alloy used on the outer shell.
1 · Reply
Mr__Man
Mr__Man Dec. 3 at 8:59 PM
$NVNO There's money to be made here
1 · Reply
hoosierfan502
hoosierfan502 Dec. 3 at 8:43 PM
$NVNO Let’s close above .40 heading into this webinar!
1 · Reply
FloFloFloFlo
FloFloFloFlo Dec. 3 at 3:07 PM
$NVNO is there a good app that tracks all of the reverse splits companies have done throughout their public listing days? And that show stock ticker name changes, too?
1 · Reply
Mr__Man
Mr__Man Dec. 1 at 5:12 PM
$NVNO An undervalued, Ben Graham type stock if ever there was one. Good luck boys, this one will pay for our Christmas. The wive's won't leave us this year, but theres always next year hahahaha
3 · Reply
herewegoagainboys
herewegoagainboys Dec. 1 at 4:27 PM
$NVNO just the beginning boys
1 · Reply
MrMillions19047
MrMillions19047 Nov. 28 at 7:38 PM
$NVNO Messages like: Buy $NVNO Dec 19 $2 Call | Enter: $0.05 Exit: $0.09 | Profit: 84.68% ROI | 1ightning.com are essentially marketing and pump attempts, not real transparency.
1 · Reply
wantothemoon
wantothemoon Nov. 28 at 3:34 PM
$NVNO lets go back to $1
0 · Reply
PLEBTRADER
PLEBTRADER Nov. 26 at 6:30 PM
$NVNO one more pump
1 · Reply